324
Participants
Start Date
May 4, 2017
Primary Completion Date
October 6, 2020
Study Completion Date
October 6, 2020
Specific blood sample of women under 50 years with acute MI
The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
Chu Hopital Nord, Marseille
Groupe Hospitalier de La Rochell, La Rochelle
Chu Dijon, Dijon
Hopital Louis Pasteur, Chartres
Chru La Cavale Blanche, Brest
Chu de Nimes, Nîmes
Hotel-Dieu Saint-Jacques, Toulouse
Chu de Montpellier, Montpellier
Chu de Rennes, Rennes
Centre Hospitalier Bretagne Atlantique, Vannes
Chru de Lille, Lille
CHU de Beauvais, Beauvais
Chu Clermont-Ferrand, Clermont-Ferrand
Centre Hospitalier de Haguenau, Haguenau
Ch St Joseph St Luc, Lyon
Centre Hospitalier Annecy Genevois, Annecy
Centre Hospitalier Rene-Dubos, Paris
Hôpital LARIBOISIERE, Paris
Hôpital Universitaire Pitié-Salpêtrière, Paris
Hopital Europeen Georges-Pompidou, Paris
Hôpital Bichat-Claude Bernard, Paris
Chu de Rouen, Rouen
Clinique St Hilaire, Rouen
Centre Hospitalier de Versailles, Versailles
Chu Amiens Picardie, Amiens
Centre Hospitalier D'Avignon, Avignon
Centre Hospitalier D'Argenteuil, Argenteuil
Centre Hospitalier D'Antibes Juan-Les-Pins, Antibes
Chu Grenoble, Grenoble
French Federation of Cardiology
OTHER
I.V.S. Institut des Vaisseaux et du Sang
UNKNOWN
Biosensors Europe SA
INDUSTRY
AstraZeneca
INDUSTRY
Boston Scientific Corporation
INDUSTRY
Abbott Medical Devices
INDUSTRY
Terumo Corporation
INDUSTRY
Daiichi Sankyo
INDUSTRY
Hexacath, France
INDUSTRY
Biotronik SE & Co. KG
INDUSTRY
French Cardiology Society
OTHER